A short conversational transcript from a YouTube video (featuring Robert Whitfield MD) discussing the prevalence and clinical impact of Cutibacterium acnes in patients from diverse geographic backgrounds. The speakers note that advanced laboratory testing (MicroGen DX) has increased detection rates, revealing the bacterium and its biofilm-forming role on implants (including but not limited to breast and shoulder implants). The conversation suggests the problem is larger than initially thought.
Chapters
It's this cutie bacteria. Now, my. Everybody listening? My patient population is not in Austin predominantly. I have patients come from all over the United States and all over the world. So I just operated before I came here on somebody from Singapore. So I think mine's a more representative analysis of a more, you know, continental United States, if you will look, versus a localized clinic. So I feel like that. And if you look in the literature, there's lots of examples of Cutibacterium acnes readily producing biofilm. You can find it on shoulder implants, because that's an area where I was.
Going to ask you if there's an issue with implants that go beyond just breasts.
Yes, yes, yes. With this bacteria especially.
Okay. All right. So you're finding all this out. You send it off to your microgen. What's it called? Microgen DX Laboratory.
Yeah.
What do you do next?
So the thing that we've gone to doing is, first of all, we're super holistic in how we approach taking care of the patient. We'll go back a little bit. So after we started running these analyses, now we kind of see the real information. So instead of seeing one positive result or two a month, now we're seeing like two or three a week because the analysis is so much more sensitive and specific to look for the bacteria.
So now we're like.
Oh, this is a lot bigger problem than we thought initially.
